Loading
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Previous close
$2.80
+$0.02 · +0.72%
Regular session · ET · Market data may be delayed.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Day range
Current $2.80
52-week range
Current $2.80
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
62
Bullish
Risk
47
Elevated Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Day range
Current $2.80
52-week range
Current $2.80
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
114.29% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI14.59M0.13%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI12.55M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM10.89M0.01%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF4.34M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN3.52M0.02%14.61B USD0.24%$224.62+0.40%
Vanguard Russell 2000 ETFVTWO1.9M0.01%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC1.45M0.10%1.49B USD0.60%$196.25+0.69%
Fidelity Enhanced Small Cap ETFFESM1.37M0.02%6.03B USD0.28%$47.36+0.21%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
